- Home
- KYN vs CNTA Comparison
KYN vs CNTA Comparison
Compare KYN & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KYN | CNTA |
|---|---|---|
| Founded | 2004 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 3.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KYN | CNTA |
|---|---|---|
| Price | $12.38 | $25.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $37.70 |
| AVG Volume (30 Days) | 561.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 8.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.79 | ★ N/A |
| Revenue Growth | N/A | ★ 118.88 |
| 52 Week Low | $7.84 | $9.60 |
| 52 Week High | $9.88 | $30.58 |
Technical Indicators
Market Signals| Indicator | KYN | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 61.36 | 41.94 |
| Support Level | $12.01 | $24.17 |
| Resistance Level | $12.23 | $26.01 |
| Average True Range (ATR) | 0.19 | 1.14 |
| MACD | 0.03 | -0.26 |
| Stochastic Oscillator | 98.87 | 18.64 |
Price Performance
Historical ComparisonAbout KYN Kayne Anderson Energy Infrastructure Fund Inc.
Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.